Liver transplantation for cholangiocarcinoma: exploring a new land
Letter to the Editor

Liver transplantation for cholangiocarcinoma: exploring a new land

Lin-Feng He1,2,3, Tao Lv1,2, Yong-Fa Huang4,5, Yao Xiao6, Gang Xu1,2, Jia-Yin Yang1,2

1Liver Transplant Center, Organ Transplant Center, West China Hospital of Sichuan University, Chengdu, China; 2Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital of Sichuan University, Chengdu, China; 3West China School of Medicine, Sichuan University, Chengdu, China; 4Liver Transplantation Center, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China; 5Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China; 6Division of Transplant Surgery, Department of Surgery and Transplant Surgery Research Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Correspondence to: Dr. Gang Xu, MD. Liver Transplant Center, Organ Transplant Center, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital of Sichuan University, 37 Guoxue Lane, Wuhou District, Chengdu 610041, China. Email: gangxu@wchscu.cn; Prof. Jia-Yin Yang, MD, PhD. Liver Transplant Center, Organ Transplant Center, Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital of Sichuan University, 37 Guoxue Lane, Wuhou District, Chengdu 610041, China. Email: doctoryjy@scu.edu.cn.

Comment on: Laughlin BS, Petersen MM, Yu NY, et al. Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. J Gastrointest Oncol 2022;13:288-9

Submitted Jun 20, 2022. Accepted for publication Aug 11, 2022.

doi: 10.21037/jgo-22-596

Liver transplantation (LTx) for cholangiocarcinoma (CCA): exploring a new land

CCA is a rare malignancy arisen from biliary system, whose incidence is increasing in these years. According to the tumor anatomical location with the second-order bile ducts, CCA is classified as intrahepatic CCA (iCCA) and extrahepatic CCA (eCCA). Surgical resection is a preferred management of cholangiocarcinoma, when radiofrequency ablation, transarterial chemoembolisation, and radiotherapy are optional treatments for those unresectable tumors (1). LTx is a considerable treatment with some liver diseases, especially early-stage hepatocellular carcinoma and is widely performed over the world, providing better prognosis. However, CCA is considered as contraindication of LTx for a long time until some studies reveal the potential management in selected patients.

Recently, Laughlin et al. published a retrospective single-center study in the Journal of Gastrointestinal Oncology and reported the different outcomes for patients with eCCA undergoing three different regimens: neoadjuvant chemoradiotherapy (nCRT) and orthotopic LTx, surgical resection and adjuvant chemoradiotherapy (aCRT), and definitive chemoradiotherapy (dCRT) (2). In their study, 20 out of 65 patients underwent orthotopic LTx after nCRT, 16 patients were treated with surgical resection and aCRT, and the rest 29 patients received dCRT only. The overall survival (OS) of patients at 3 and 5 years in nCRT group (78% and 59%) and aCRT group (49% and 38%) was significantly improved than that in dCRT group (16% and 0%), resulting from treatment strategy only in multivariate analysis. Also, the local progression-free survival and disease-free survival were higher in nCRT group (50% and 61%) and aCRT group (30% and 30%) than these in dCRT group (0% and 0%). Unlike poor outcomes reported in LTx treatment alone, undergoing nCRT before LTx improved the prognosis. In the era of neoadjuvant treatment for CCA combining LTx with chemoradiotherapy, this research provides a new potential approach to manage some featured patients with eCCA.

For CCA, the treatments are limited, especially for unresectable tumors, and risk of recurrence is high (3,4). So, good survivals of LTx treatment are encouraging. LTx for eCCA, especially perihilar CCA (pCCA), began long times ago but the outcomes were not so satisfactory until the use of neoadjuvant chemoradiotherapy before LTx in Mayo protocol (5). In the protocol, patients should be with pathologically confirmed pCCA or evaluated carbohydrate antigen 19-9 (>100 ng/mL) with radiologically malignant stricture. Besides, the size of tumor should be under 3 cm without distant metastases and lymph node metastases. Appropriate patients will receive a consecutive therapy of external-beam irradiation with intravenous 5-fluorouracil (5-FU), brachytherapy and oral maintenance capecitabine when they are waiting for LTx. The 5-year OS of patient was up to 82%. A more recent multi-center retrospective research also reported similar result in strict selected patients with pCCA undergoing neoadjuvant regime of Mayo protocol (6). Patients undergoing LTx had better OS (3-year: 72%; 5-year: 54%) than that of resection (3-year: 44%; 5-year: 19%). Similarly, a meta-analysis involving 428 patients shows improved 5-year OS rates and less recurrence in neoadjuvant chemoradiation group (65.1%; 24.1%) compared to the LTx only (31.6%; 51.7%) (7).

Regime of neoadjuvant chemoradiation before LTx is also suitable for iCCA. Sapisochin et al. perform a retrospective multicenter study on neoadjuvant chemoradiation before LTx in very early iCCA, defined as single tumors ≤2 cm. The 5-year OS is better in very early iCCA group (65%) than that in advanced iCCA group (45%). Meanwhile, the 5-year cumulative risk of recurrence in very early iCCA group (18%) is lower than that in advanced iCCA group (61%). Interestingly, McMillan et al. provided good outcomes for patients with locally-advanced, unresectable iCCA receiving LTx after neoadjuvant therapy (8). The locally-advanced, unresectable iCCA is defined as a single tumor ≥2 cm or multiple tumors without distant metastases, lymph node metastases and encasement or involvement of major vascular structures. Patients received neoadjuvant therapy for 6 months and disease should be stable without extrahepatic disease before LTx was performed. The OS at 1-, 3-, and 5-year is 100%, 71%, and 57%, which supported LTx with neoadjuvant therapy as an effective regime for locally-advanced, unresectable iCCA.

In summary, some highly-selected patients with CCA may be the potential candidate for LTx along with neoadjuvant chemoradiation. Remarkably, the roles of LTx as a reasonable therapeutic strategy for CCA is being extensively studied (Table 1) and we await the outcomes of large-scale randomized prospective studies. Additionally, targeted therapy and immunotherapy are widely applied to the treatment of cholangiocarcinoma as more and more molecular therapeutic targets of are revealed (9,10). Combining targeted therapy and immunotherapy with neoadjuvant therapy before LTx may lead to a more satisfying prognosis.

Table 1

Recruiting prospective clinical trials of liver transplantation for cholangiocarcinoma

Type Estimated participants Stage Combined therapy Institution/country Study start date Estimated study completion date Phase ClinicalTrials.gov ID
iCCA 30 Very early NA University Health Network, Canada April 2018 January 2029 Phase II NCT02878473
iCCA 15 Unresectable nCRT Oslo University Hospital, Norway June 2020 May 2035 NA NCT04556214
pCCA 15 Unresectable nCRT Oslo University Hospital, Norway September 2021 May 2045 NA NCT04993131
pCCA 34 Unresectable nCRT Hospital Vall d'Hebron, Spain April 2020 June 2025 NA NCT04378023
CCA 100 Unresectable nCRT Washington University School of Medicine, USA August 2005 December 2022 NA NCT00301379

iCCA, intrahepatic cholangiocarcinoma; pCCA, perihilar cholangiocarcinoma; NA, not applicable; nCRT, neoadjuvant chemoradiotherapy.

Acknowledgments

Funding: This study was supported by the National Natural Science Foundation of China (No. 82070674), the Natural Science Foundation of Sichuan Province (No. 2022NSFSC0843), the Sichuan Science and Technology Program (No. 2019YFG0036), the China Postdoctoral Science Foundation (No. 2022M712262).

Footnote

Provenance and Peer Review: This article was a standard submission to the journal. The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-596/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

  1. Zhang W, Song T. Adjuvant therapy for intrahepatic carcinoma after surgical resection: chemotherapy and future perspectives. Hepatobiliary Surg Nutr 2021;10:878-80. [Crossref] [PubMed]
  2. Laughlin BS, Petersen MM, Yu NY, et al. Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. J Gastrointest Oncol 2022;13:288-97. [Crossref] [PubMed]
  3. Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. Nat Rev Dis Primers 2021;7:65. [Crossref] [PubMed]
  4. Qu WF, Liu WR, Shi YH. Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: far from a clinical consensus. Hepatobiliary Surg Nutr 2021;10:887-9. [Crossref] [PubMed]
  5. Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 2004;24:201-7. [Crossref] [PubMed]
  6. Ethun CG, Lopez-Aguiar AG, Anderson DJ, et al. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg 2018;267:797-805. [Crossref] [PubMed]
  7. Cambridge WA, Fairfield C, Powell JJ, et al. Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma. Ann Surg 2021;273:240-50. [Crossref] [PubMed]
  8. McMillan RR, Javle M, Kodali S, et al. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant 2022;22:823-32. [Crossref] [PubMed]
  9. Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol 2021;32:1111-26. [Crossref] [PubMed]
  10. Eso Y, Seno H. Optimization of immunotherapy for patients with hepatobiliary cancer. Hepatobiliary Surg Nutr 2021;10:717-9. [Crossref] [PubMed]
Cite this article as: He LF, Lv T, Huang YF, Xiao Y, Xu G, Yang JY. Liver transplantation for cholangiocarcinoma: exploring a new land. J Gastrointest Oncol 2022;13(5):2696-2698. doi: 10.21037/jgo-22-596

Article Options

Download Citation

Share